Catalent Inc Stock News

Stock futures indicate major Wall Street indices are expected to open lower this week that will see a crucial speech by Federal Reserve Chair Jerome Powell at the Economic Club of Washington on Tuesda

Catalent (NYSE: CTLT ), which manufactures pharmaceutical products, is soaring more than 20% in early trading today. Over the weekend, Bloomberg reported that Danaher (NYSE: DHR ) is potentially inter

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Life Sciences Company Danaher Corp. DHR, -0.31% is interested in taking over contract manufacturer Catalent Inc. CTLT, -1.04% and is willing to pay a significant premium for the company, Bloomberg rep

Medical equipment maker Danaher Corp has expressed interest in taking over contract drugmaker Catalent Inc , Bloomberg News reported on Saturday, citing people familiar with the matter.

Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 5 1 0 0 Last 30D

Barclays has decided to maintain its Overweight rating of Catalent (NYSE:CTLT) and lower its price target from $62.00 to $58.00. Shares of Catalent are trading down 3.19% over the last 24 hours, at $5

Remember all the beat-up stocks investors wrote off last year? In an interesting twist, last year's worst stocks are turning into the first.

SOMERSET, N.J.--( BUSINESS WIRE )--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patien

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Investors were net sellers of Catalent equity across the back end of 2022. Much of the downside is explained by diminishing Covid-19 revenues and potential near-term challenges to earnings quality.